Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Health Care

57.82
+0.77171.35%
Post-market: 57.82-0.00170.00%19:30 EDT
Volume:4K
Turnover:235.03K
Market Cap:93.67M
PE:- -
High:57.82
Open:56.69
Low:56.69
Close:57.05
52wk High:64.60
52wk Low:42.76
Shares:1.62M
Float Shares:1.62M
Volume Ratio:0.17
T/O Rate:0.25%
Dividend:0.63
Dividend Rate:1.10%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Lilly's Next-Gen Obesity Efforts Could Tip Scales Further in Its Favor, Citi Says

Reuters
·
Sep 24

Alert on EOG CFO Appointment Incorrectly Tagged to J&J Withdrawn

Reuters
·
Sep 24

EOG Resources Announces Ann Janssen's Retirement and Jeff Hibbard as Next CFO

THOMSON REUTERS
·
Sep 24

UnitedHealth Adds Jodee Kozlak as Chief Administrative Officer Effective Sept. 28, 2026

Reuters
·
Sep 24

UnitedHealth Group Announces Addition to Leadership Team

THOMSON REUTERS
·
Sep 24

UnitedHealth - Appoints Jodee Kozlak as Chief Administrative Officer Effective Sept. 28, 2026

THOMSON REUTERS
·
Sep 24

Merck's Drug for Diabetes-Related Eye Disease Meets Trial Goal

Reuters
·
Sep 24

Health Canada Approves AbbVie’s Epkinly Combo for Relapsed or Refractory Follicular Lymphoma in Adults

Reuters
·
Sep 24

Epkinly® Receives Health Canada Approval for Adults with Follicular Lymphoma

THOMSON REUTERS
·
Sep 24

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Dow Jones
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

THOMSON REUTERS
·
Sep 24

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 24

Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 24